Trial Profile
A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients With Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Ivaltinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors CrystalGenomics
- 11 Sep 2023 Planned End Date changed from 1 Sep 2022 to 1 Dec 2023.
- 11 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2022 Planned End Date changed from 1 Dec 2019 to 1 Sep 2022.